Search

Displaying results 5691 - 5700 of 7283 in total
  1. Drug

    Rimiducid

    go.drugbank.com/drugs/DB04974
    Investigational

    Rimiducid is a lipid-permeable tacrolimus analogue and a protein dimerizer.

  2. Drug

    Tigapotide

    go.drugbank.com/drugs/DB04985
    Investigational

    Tigapotide is a synthetic 15-mer peptide that is derived from the natural sequence of amino acids of the prostate secretory protein (PSP94), one of three predominant proteins found in human seminal fluid

  3. Drug

    Ty800

    go.drugbank.com/drugs/DB04989
    Investigational

    Ty800 is a vaccine designed to offer rapid, oral, single-dose protection against <i>Salmonella typhi</i>, the cause of typhoid fever.

  4. Drug

    Adecatumumab

    go.drugbank.com/drugs/DB05006
    Investigational

    Adecatumumab is a recombinant human monoclonal antibody of the IgG1 subclass with a binding specificity to epithelial cell adhesion molecule (EpCAM). … EpCAM (CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer.

  5. Drug

    SGS-742

    go.drugbank.com/drugs/DB05010
    Investigational

    SGS-742 has been used in trials studying the treatment of Seizures and Metabolic Disease.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    XL999

    go.drugbank.com/drugs/DB05014
    Investigational

    XL999 induces a cell-cycle block by a mechanism distinct from those previously identified and exhibits broad antitumor activity in xenograft models. … XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth promoting and angiogenic properties, including FGFR 1/3, PDGFRα/β, VEGFR2/KDR, KIT, and FLT3.

  7. Drug

    Ataluren

    go.drugbank.com/drugs/DB05016
    ApprovedWithdrawn

    Ataluren is a novel, orally administered drug that targets nonsense mutations. … Ataluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk.

  8. Drug

    Lunacalcipol

    go.drugbank.com/drugs/DB05024
    Investigational

    CTA018 is a member of a new class of vitamin D analogues with a dual mechanism of action, called Vitamin D Signal Amplifiers. … This proprietary new drug is both a potent inhibitor of CYP24 (the enzyme responsible for the breakdown of vitamin D) and a potent activator of vitamin D signaling pathways.

  9. Drug

    Anatibant

    go.drugbank.com/drugs/DB05038
    Experimental

    Anatibant is a selective, very potent, small-molecule Bradykinin B2 receptor antagonist. It is developed for the for the treatment of traumatic brain injury (TBI).

  10. Drug

    PSN357

    go.drugbank.com/drugs/DB05044
    Experimental

    PSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.